Oral combination therapy with thiazolidinediones in type 2 diabetes

American Journal of Managed Care

Volumn 12, Issue SUPPL. 14, 2006, Pages

  LaSalle, James R ^a   Cross, L Brian ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; CHOLESTEROL; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DUETACT; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLICLAZIDE; GLIMEPIRIDE; GLIMEPIRIDE PLUS ROSIGLITAZONE; GLIPIZIDE; GLIPIZIDE PLUS METFORMIN; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGLITINIDE; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; TRIACYLGLYCEROL; UNINDEXED DRUG;

ARTICLE; BODY FAT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DIABETIC ANGIOPATHY; DISEASE COURSE; DRUG ACTIVITY; DRUG DOSE TITRATION; DRUG MECHANISM; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIVER TOXICITY; LUNG EDEMA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VASCULAR DISEASE; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT GAIN;; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; THIAZOLIDINEDIONES; UNITED STATES;

EID: 33845302955     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. LaSalle JR. Management of type 2 diabetes: focus on the thiazolidinediones. Hosp Physician. 2005;41:37-42, 46.
2. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 1992;15:318-368.
3. Reaven GM. Rathophysiology of insulin resistance in human disease. Physiol Rev. 1995;75:473-486.
4. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45:1661-1669.
5. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care. 2006;29(suppl 1):S4-S42. Erratum in: Diabetes Care. 2006;29:1192.
6. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes. 1995; 44:1249-1258. Erratum in: Diabetes. 1996;45:1655.
7. Lebovitz HE. Insulin secretagogues: old and new. Diabetes Rev. 1999;7:139-153.
8. Khaw KT, Wareham N, Bingham S, et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004;141:413-420.
9. Beckley ET. ADA Scientific Sessions: retinopathy found in pre-diabetes. DOC News. 2005;2:1. Available at: http://docnews.diabetesjournals.org/cgi/ content/full/2/8/1-a. Accessed October 11, 2006.
10. Brunzell JD, Hokanson JE. Dyslipidemia of central obesity and insulin resistance. Diabetes Care. 1999;22 (suppl 3):C10-C13.
11. Kendall DM, Sobel BE, Coulston AM, et al. The insulin resistance syndrome and coronary artery disease. Coron Artery Dis. 2003;14:335-348.
12. Unger RH. Lipotoxic diseases. Annu Rev Med. 2002;53:319-336.
13. Bell DS. Management of type 2 diabetes with thiazolidinediones: link between beta-cell preservation and durability of response. Endocrinologist. 2004;14:293-299.
14. Kaneto H, Fujii J, Myint T, et al. Reducing sugars trigger oxidative modification and apoptosis in pancreatic beta-cells by provoking oxidative stress through the glycation reaction. Biochem J. 1996;320(pt 3):855-863.
15. Matsuoka T, Kajimoto Y, Watada H, et al. Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells. J Clin Invest. 1997;99:144-150.
16. Kim WH, Lee JW, Suh YH, et al. Exposure to chronic high glucose induces beta-cell apoptosis through decreased interaction of glucokinase with mitochondria: downregulation of glucokinase in pancreatic beta-cells. Diabetes. 2005;54:2602-2611.
17. De Leon DD, Crutchlow MF, Ham JY, Stoffers DA. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. Int J Biochem Cell Biol. 2006;38:845-859.
18. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153-165.
19. Rotella CM, Pala L, Mannucci E. Glucagon-like peptide 1 (GLP-1) and metabolic diseases. J Endocrinol Invest. 2005;28:746-758.
20. Lebovitz HE, Austin MM, Blonde L, et al. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract. 2006;12(suppl 1):6-12.
21. American College of Endocrinology consensus statement on guidelines for glycemic control. Endocr Pract. 2002;8(suppl 1):5-11.
22. Cheng AY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ. 2005;172:213-226.
23. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287:360-372.
24. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963-1972.
25. Starlix (nateglinide) product information. Novartis; January 2004. Available at: http://www.pharma.us. novartis.com/product/pi/pdf/Starlix.pdf. Accessed October 11, 2006.
26. Prandin (repaglinide) product information. Novo Nordisk; June 2006. Available at: http://www.prandin. com/docs/prandin_insert.pdf. Accessed October 11, 2006.
27. Precose (acarbose) product information. Bayer Pharmaceuticals; November 2004. Available at: http://www.univgraph.com/bayer/inserts/precose.pdf. Accessed October 11, 2006.
28. Glyset (miglitol) product information. Pfizer; October 2004. Available at: http://www.pfizer.com/pfizer/download/uspi_glyset.pdf. Accessed October 11, 2006.
29. Januvia (sitagliptin) product information. Merck & Co; 2006. Available at: http://www.merck.com/product/usa/pi_circulars/j/januvia/ januvia_pi.pdf. Accessed November 3, 2006.
30. Simpson SH, Majumdar SR, Tsuyuki RT, et al. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ. 2006;174:169-174.
31. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853. Erratum in: Lancet. 1999;354:602.
32. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854-865. Erratum in: Lancet. 1998;352:1558.
33. Kendall DM. Thiazolidinediones: the case for early use. Diabetes Care. 2006;29:154-157.
34. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med. 2001;134:61-71. Erratum in: Ann Intern Med. 2001;135:307.
35. Bell DS. Beta-cell rejuvenation with thiazolidinediones. Am J Med. 2003;115(suppl 8A):20S-23S.
36. Bell DS. A comparison of agents used to manage type 2 diabetes mellitus: need for reappraisal of traditional approaches. Treat Endocrinol. 2004;3:67-76.
37. Derosa G, Cicero AF, D'Angelo A, et al. Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens Res. 2005;28:917-924.
38. Ovalle F, Bell DS. Lipoprotein effects of different thiazolidinediones in clinical practice. Endocr Pract. 2002;8:406-410.
39. Serdy S, Abrahamson MJ. Durability of glycemic control: a feature of the thiazolidinediones. Diabetes Technol Ther. 2004;6:179-189.
40. Derosa G, Cicero AF, Gaddi A, et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract. 2005;69:5-13.
41. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289.
42. Actos (pioglitazone) product information. Takeda Pharmaceutical Company; July 2006. Available at: http://www.actos.com/pi.pdf. Accessed October 11, 2006.
43. Avandia (rosiglitazone) product information. GlaxoSmithKline; June 2006. Available at: http://us.gsk. com/products/assets/us_avandia.pdf. Accessed October 11, 2006.
44. Marcy TR, Britton ML, Blevins SM. Second-generation thiazolidinediones and hepatotoxicity. Ann Pharmacother. 2004;38:1419-1423.
45. Abrahamson MJ. Clinical use of thiazolidinediones: recommendations. Am J Med. 2003;115(suppl 8A):116S-120S.
46. Wyne KL, Drexler AJ, Miller JL, et al. Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones. Postgrad Med. 2003;Spec No:63-72.
47. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005-2012.
48. Tan MH, Baksi A, Krahulec B, et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care. 2005;28:544-550.
49. Matthews DR, Charbonnel BH, Hanefeld M, et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev. 2005;21:167-174.
50. Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia. 2005;48:1093-1104.
51. Roden M, Laakso M, Johns D, et al. Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with type 2 diabetes mellitus. Diabet Med. 2005;22:1101-1106.
52. Virtanen KA, Hallsten K, Parkkola R, et al. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes. 2003;52:283-290.
53. Nagasaka S, Aiso Y, Yoshizawa K, Ishibashi S. Comparison of pioglitazone and metformin efficacy using homeostasis model assessment. Diabet Med. 2004;21:136-141.
54. Weissman P, Goldstein BJ, Rosenstock J, et al. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE study. Curr Med Res Opin. 2005;21:2029-2035.
55. Bailey CJ, Bagdonas A, Rubes J, et al. Rosiglitazone/ metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. Clin Ther. 2005;27:1548-1561.
56. Rosenstock J, Goldstein BJ, Vinik AI, et al. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs SULphonylurea Titration (RESULT) study. Diabetes Obes Metab. 2006;8:49-57.
57. Melikian C, White TJ, Vanderplas A, et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther. 2002;24:460-467.
58. Vanderpoel DR, Hussein MA, Watson-Heidari T, et al. Improved adherence with rosiglitazone/metformin fixed-dose combination therapy: a retrospective analysis. Presented at the 64th Annual Scientific Sessions of the American Diabetes Association; June 4-8, 2004; Orlando, FL. Abstract 2014-PO. Available at: http://scientificsessions.diabetes.org/Abstracts/index.cfm? fuseaction=Locator.DisplayAbstractSearch&CFID=11740 &CFTOKEN=78208199. Accessed October 11, 2006.
59. Rosenstock J, Strow L, Rood J, et al. Rosiglitazone/metformin (RSC/MET) fixed dose combination (FDC) is effective and well-tolerated in drug-naïve type 2 diabetes mellitus (T2DM) subjects with severe hyperglycemia. Presented at the 65th Annual Scientific Sessions of the American Diabetes Association; June 10-14, 2005; San Diego, Calif. Abstract 515-P. Available at: http://scientificsessions.diabetes.org/Abstracts/index.cfm? fuseaction=Locator. DisplayAbstractSearch&CFID=11740 &CFTOKEN=78208199. Accessed October 11, 2006.
60. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283:1695-1702. Erratum in: JAMA. 2000;284:1384.
61. Shearer A, Bagust A, Ampudia-Blasco J, Martinez-Lage B. Clinical and cost-effectiveness of rosiglitazone-metformin combination in patients with type-2 diabetes in Spain. Presented at the 64th Annual Scientific Sessions of the American Diabetes Association; June 4-8, 2004; Orlando, FL. Abstract 1204-P. Available at: http://scien tificsessions.diabetes.org/Abstracts/index.cfm? fuseaction =Locator.DisplayAbstractSearch&CFID=11740& CFTOKEN=78208199. Accessed October 11, 2006.
62. Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin. 2006;22:751-759.
63. Derosa G, Gaddi AV, Piccinni MN, et al. Differential effects of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. Diabetes Obes Metab. 2006;8:197-205.
64. Garber A, Klein E, Bruce S, et al. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2006;8:156-163.
65. Kerenyi Z, Samer H, James R, et al. Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2004;63:213-223.
66. Baksi A, James RE, Zhou B, Nolan JJ. Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea. Acta Diabetol. 2004;41:63-69.
67. Herman WH, Dirani RG, Horblyuk R, et al. Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study. Am J Manag Care. 2005;11:273-278.
68. Hanefeld M, Brunetti P, Schernthaner GH, et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2004;27:141-147.